Ozanimod (new indication: ulcerative colitis, pre-treated patients)


  • Active Substance: Ozanimod
  • Name: Zeposia®
  • Therapeutic area: Ulcerative colitis
  • Pharmaceutical company: Bristol-Myers Squibb GmbH & Co. KGaA

Time table:

  • Start: 15.12.2021
  • Final decision by G-BA: 16.06.2022

Final decision:

  • Adult patients who have an intolerance or contraindication to conventional therapy:
    No additional benefit proved
  • Adult patients who are intolerant or have an inadequate or no response to a biologic (TNF-α antagonist or integrin inhibitor or interleukin inhibitor):
    No additional benefit proved